Breast cancer screening policies in developing countries: A cost-effectiveness analysis for India

Journal of the National Cancer Institute

Volumn 100, Issue 18, 2008, Pages 1290-1300

  Okonkwo, Quirine Lamberts ^a,b   Draisma, Gerrit ^a   Der Kinderen, Arno ^a   Brown, Martin L ^c   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Institute for Health Sciences   (Netherlands)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; FEMALE; GROUPS BY AGE; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HUMAN; INDIA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PALLIATIVE THERAPY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UNITED STATES; WORLD HEALTH ORGANIZATION;

ADULT; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; INDIA; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PALPATION; PREDICTIVE VALUE OF TESTS;

EID: 52449098037     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn292     Document Type: Article

References (48)

1. de Koning HJ. Mammographic screening: evidence from randomised controlled trials. Ann Oncol. 2003;14(8):1185-1189.
2. Shapiro S, Coleman EA, Broeders M, et al. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol. 1998;27(5):735-742.
3. The World Bank. 2001. http://www.worldbank.org/date/countryclass/.
4. Mathers CD, Lopez AD, Murray CJL. The burden of disease and mortality by condition: data, methods and results for 2001. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, eds. Global Burden of Disease and Risk Factors. New York: Oxford University Press; 2006, pp. 45-240
5. Advani S. Partner profile: cancer in India. INCTR Newsl. 2004;5(2). http://www.inctr.org/publications/2004_v05_n02_a09.shtml.
6. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5, Lyon, France: International Agency for Research on Cancer and World Health Organization; 2001.
7. Nandakumar A, Anantha N, Venugopal TC. Population-based survival from breast and cervical cancer and lymphoreticular malignancies in Bangalore. India. IARC Sci Publ. 1998;145:61-68.
8. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents Vol. VIII. Lyon, France: IARC; 2004;.
9. Sankaranarayanan R, Black RJ, Swaminathan R, Parkin DM. An overview of cancer survival in developing countries. IARC Sci Publ. 1998;145:135-173.
10. Chopra R. The Indian scene. J Clin Oncol. 2001;19(18 suppl):106S-111S.
11. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(suppl 8):S4-S66.
12. Yeole BB, Jayant K, Jussawalla DJ. Trends in breast cancer incidence in greater Bombay: an epidemiological assessment. Bull World Health Organ. 1990;68(2):245-249.
13. Chopra R. The Indian scene. J Clin Oncol. 2001;19(18 suppl):106S-111S.
14. Dinshaw KA, Shastri SS, Patil SS. Cancer Control Programme in India: challenges for the new millenium. Health Adm. 2005;XVII(1):10-15 http://medind.nic.in/haa/t05/i1/haat05i1p10.pdf.
15. Kingsbury K. Global breast cancer: the changing face of breast cancer. Time Specials. 2007. http://www.time.com/time/specials/2007/article/0, 28804,1666089_1666563,00.html.
16. Smith RA, CaleffiM, Albert US, et al. Breast cancer in limited-resource countries: early detection and access to care. Breast J. 2006;12(suppl 1):S16-S26.
17. Rijnsburger AJ, van Oortmarssen GJ, Boer R, et al. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. Int J Cancer. 2004;110(5):756-762.
18. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87(16):1217-1223.
19. van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer. 1990;66(7):1601-1612.
20. van den Akker-van Marle E, de Koning H, Boer R, van der MP. Reduction in breast cancer mortality due to the introduction of mass screening in The Netherlands: comparison with the United Kingdom. J Med Screen. 1999;6(1):30-34.
21. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet. 2003;361(9367):1411-1417.
22. Paci E, Boer R, Zappa M, et al. A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme in the city of Florence, Italy. Eur J Cancer. 1995;31A(3):348-353.
23. van den Akker-Van Marle ME, Reep-van den Bergh CM, Boer R, Del Moral A, Ascunce N, de Koning HJ. Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round. Int J Cancer. 1997;73(4):464-469.
24. van den Akker-Van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst. 2002;94(3):193-204.
25. Fracheboud J, de Koning HJ, Beemsterboer PM, et al. Interval cancers in the Dutch breast cancer screening programme. Br J Cancer. 1999;81(5):912-917.
26. Fracheboud J, Otto SJ, Ja vD, et al. Decreased rates of advanced breast cancer due to mammography screening in the Netherlands. Br J Cancer. 2004;91(5):861-867.
27. Groenewoud JH, Pijnappel RM, Me vdA-VM, et al. Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy. Br J Cancer. 2004;90(2):383-392.
28. Collette C, Collette HJ, Fracheboud J. Evaluation of a breast cancer screening programme - the DOM project. Eur J Cancer. 1992;28A(12):1985- 1988.
29. Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer. 2004;91(2):242-247
30. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315(9):559-563.
31. Bobo JK, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst. 2000;92(12):971-976.
32. Nandakumar A, Anantha N, Venugopal TC, Sankaranarayanan R, Thimmasetty K, Dhar M. Survival in breast cancer: a population-based study in Bangalore, India. Int J Cancer. 1995;60(5):593-596.
33. United Nations Population Division. India, Population by Five-year Age Group and Sex (Thousands), Medium Variant, 2000, 2002. http://esa.un.org/ unpp/.
34. WHO. Life Tables for 191 Countries, World Mortality in 2000, 2004. http://www.who.int/whosis/database/life_tables/life_tables.cfm.
35. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer. 1991;49(4):531-537.
36. WHO. Purchasing Power Parity, World Health Organization. 2004. http://www.who.int/choice/costs/ppp/en/index.html.
37. Mulligan J, Fox-Rushby JA, Adam T, Johns B, Mills A. Unit Costs of Delivering Health Interventions in Low- and Middle-Income Countries. 2003. Working Paper No. 9. Bethesda, MD: Disease Control Priorities Project (DCPP). http://www.dcp2.org/file/24/wp9.pdf.
38. de Koning HJ. Breast cancer screening; cost-effective in practice? Eur J Radiol. 2000;33(1):32-37.
39. Boer R, van Ballegooijen M, Meerding, W-J, Singh V, Sehgal A, Habbema JDF. Unaided visual examination of the cervix versus PAP-smears for early detection of cervical cancer. In: Monsonego J, ed. Eurogin 2000. 4th International Multidisciplinary Congress, April 5-9, Paris. Bologna: Monduzzi Editore SpA; 2000, pp. 55-63.
40. Agarwal SP. Health sector in India - progress, challenges and the way forward. J Indian Med Assoc. 2005;103(12):692, 694, 696-698.
41. Kim JJ, Salomon JA, Weinstein MC, Goldie SJ. Packaging health services when resources are limited: the example of a cervical cancer screening visit. PLoS Med. 2006;11(3):e434.
42. Michaelson JS, Silverstein M, Wyatt J, et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer. 2002;95(4):713-723.
43. Mittra I, Badwe RA, Desai PB, Yeole BB, Jussawalla DJ. Early detec tion of breast cancer in developing countries. Lancet. 1989;1(8640):719-720.
44. Dinshaw KA, Shastri SS, Singh S, et al. Screening for cervix and breast cancer in Mumbai slums. INCTR Newsl. 2003;4(1):http://www.inctr.org/ publications/2003_v04_n01_s02.shtml.
45. Sarin R. Indian National Cancer Control Programme: setting sight on shifting targets. J Cancer Res Ther. 2005;1(4):240-248.
46. Eniu A, Carlson RW, Aziz Z, et al. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J. 2006;12(suppl 1):S38-S53.
47. Groot MT, Baltussen R, Uyl-de Groot CA, Anderson BO, Hortobagyi GN. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J. 2006;12(suppl 1):S81-S90.
48. WHO. Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeceonomics and Health. Chaired by Jeffrey D. Sachs, Presented to Gro Harlem Brundtland, Director-General of the World Health Organization. December 20, 2001. Geneva, Switzerland: World Health Organization.